Drug Caucus Hearing on Barriers to Cannabidiol Research

WASHINGTON — The Senate Caucus on International Narcotics Control, led by Sen. Chuck Grassley and Sen. Dianne Feinstein, will hold a hearing entitled  “Cannabidiol: Barriers to Research and Potential Medical Benefits.”  The hearing will address the complexities involved with conducting research on cannabidiol, a Schedule I substance, as well as its potential medical benefits and risks in treating serious illnesses such as intractable epilepsy. Additionally, the hearing will focus on the regulatory oversight of products containing cannabidiol. 

When:              9:30 a.m. Eastern, Wednesday, June 24, 2015

Where:             226 Dirksen Senate Office Building, Washington, D.C.

Witness list:

Panel One:      

– Mr. Joseph Rannazzisi, Deputy Assistant Administrator of Drug Diversion with the Drug Enforcement Administration (DEA), Washington, D.C.

– Dr. Douglas Throckmorton, Deputy Director for the Center for Drug Evaluation and Research, Food and Drug Administration, Washington, D.C.

– Dr. Nora Volkow, Director, National Institute on Drug Abuse, Washington, D.C.

Panel Two:

– Dr. John “Brad” Ingram, Child Neurologist, University of Mississippi Medical Center, Jackson, Mississippi

– Dr. Tom Minahan, Emergency Room Physician, Arrowhead Regional Medical Center, Colton, California

– Dr. Kevin Sabet, Co-Founder, Project SAM (Smart Approaches to Marijuana), Cambridge, Massachusetts